|3 Regimens Hold HIV in Check Without Efavirenz|
About 1% of patients on raltegravir discontinued treatment due to toxicity compared with 5% of patients on darunavir and 16% of those on atazanavir, largely due to clinical jaundice and hyperbilirubinemia with atazanavir. Gastrointestinal symptoms were ...
MedPage Today - Sat, 08 Mar 2014 01:00
|Three NNRTI-sparing regimens equally effective as first-line HIV treatment|
Healio - Fri, 07 Mar 2014 11:52
|New 96-Week ACTG Study Results Presented at CROI 2014; First Large Study ...|
One percent, 16 percent and five percent discontinued ISENTRESS, atazanavir/r and darunavir/r, respectively, for toxicity largely due to clinical jaundice and hyperbilirubinemia with atazanavir/r, and gastrointestinal symptoms with both atazanavir/r ...
MarketWatch - Wed, 05 Mar 2014 09:15
|New drugs trump interferon in HCV therapy|
Adverse events included mild hyperbilirubinemia in some patients and interferon side effects. Simeprevir in coinfection. Dr. Dietrich was also the lead on study C212, which looked at simeprevir (Olysio) on a PR backbone in coinfected patients. The ...
Family Practice News Digital Network - Wed, 05 Mar 2014 09:48
|Bristol-Myers Squibb Presents Promising Phase IIb Data for Novel ...|
Hyperbilirubinemia: Reversible, asymptomatic elevations in indirect (unconjugated) bilirubin occurred in most patients treated with REYATAZ (atazanavir sulfate). There are no long-term safety data for patients with persistent elevations in total ...
PipelineReview.com (press release) - Wed, 05 Mar 2014 22:22
|Nieuwe behandelmogelijkheden voor ernstige geelzucht bij pasgeborenen en ...|
Schreuder werkt nu als arts-assistent kindergeneeskunde in het Medisch Centrum Leeuwarden. De titel van haar proefschrift luidt: “Diagnosis and treatment of unconjugated hyperbilirubinemia: experimental and clinical aspects”. Bericht delen via Facebook ...
Westerwolde actueel - Mon, 10 Feb 2014 01:56